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Abstract
Background:  Stress echocardiography is a cost-effective tool for the modern noninvasive
diagnosis of coronary artery disease. Several physical and pharmacological stresses are used in
combination with echocardiographic imaging, usually exercise, dobutamine and dipyridamole. The
safety of a stress is (or should be) a major determinant in the choice of testing. Although large scale
single center experiences and multicenter trial information are available for both dobutamine and
dipyridamole stress echo testing, complications or side effects still can occur even in the most
experienced laboratories with the most skilled operators.
Case presentation: We decided to present a case collection of severe complications during
pharmacological stress echo testing, including a ventricular tachycardia, cardiogenic shock,
transient ischemic attack, torsade de pointe, fatal ventricular fibrillation, and free wall rupture.
Conclusion:  We believe that, in this field, every past complication described is a future
complication avoided; what happens in your lab is more true of what you read in journals; and
Good Clinical Practice is not "not having complications", but to describe the complications you had.
Background
The safety of the stress test is a major issue in deciding its
practicability and cost-effectiveness – yet, many major
complications remain "unmentioned and unheard", for
several reasons – mainly related to the "file drawer" bias,
lack of time ("busy agenda bias") or unfamiliarity with
the technicalities of scientific communication (editorial
"black box bias").
Stress echocardiography is a cost-effective tool for the
modern noninvasive diagnosis of coronary artery disease
[1]. Several physical and pharmacological stresses are
used in combination with echocardiographic imaging,
usually exercise, dobutamine and dipyridamole. The
safety of a stress is (or should be) a major determinant in
the choice of testing. Although large scale single center
experiences and multicenter trial information are availa-
ble for both dobutamine and dipyridamole [2-6] stress
echo testing, complications or side effects still can occur
even in the most experienced laboratories with the most
skilled operators. We believe that, in this field, every past
complication described is a future complication avoided;
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what happens in your lab is more true than what you read
in journals; and Good Clinical Practice is not "not having
complications", but to describe the complications you
had. Therefore, we decided to present an unusual case
series, consisting in a collection of severe complications
during pharmacological stress echo testing.
Case presentation
Case 1
A 73 year-old male patient, with a previous PTCA (percu-
taneous transluminal coronary angioplasty) of the left
anterior descending artery and ramus intermedius, under-
went a dipyridamole stress testing following a nondiag-
nostic exercise EKG (the exercise was terminated because
of the occurrence of non sustained ventricular tachycar-
dia). The baseline echo revealed an apical hypokinesis
(additional file 1) which did not change during the test,
however ventricular tachycardia developed again during
dipyridamole echo (additional file 2). Lesson: it is useless
to expose a patient with known coronary artery disease
and a previously complicated test to another stressor.
Indication must be appropriate.
Case 2
An 81 year-old female, with symptomatic and hemody-
namically significant aortic stenosis and normal coronary
angiogram underwent a high dose dipyridamole stress
echo testing. The baseline wall motion was normal (addi-
tional file 3). The patient fell in cardiogen shock and had
a transient ischemic attack of the brain following a nega-
tive test (additional file 4). Lesson: another dangerous
experiment on a patient with already diagnosed normal
coronary arteries. Indication must be always appropriate.
Case 3
A 57 year-old male patient with abdominal pain and clau-
dicatio intermittens was studied with dobutamine
echocardiography. Soon after the first (5 mcg/Kg/min)
dose the patient had ventricular extrasystoles (additional
file 5) and during the 20 mcg/Kg/min dose of dob-
utamine, Torsade de points ventricular tachycardia
evolved (additional file 6). Lesson: in patients with arrhyt-
mias in resting conditions, dobutamine can often provoke
dangerous tachycardias. In this group of patients dipyrida-
mole could be the first choice.
Case 4
A 55 year-old male patient with previous posterior myo-
cardial infarction, quadruple by-pass, depressed left ven-
tricular function and chest pain was sent to the echo lab
for assessment of myocardial viability (additional file 7).
Low dose dobutamine echo was performed, however, fol-
lowing the 10 mcg/Kg/min dose a fatal ventricular fibril-
lation developed (additional file 8). Lesson: there must
always be an attending physician during pharmacological
stress echo testing with all necessary equipment for reani-
mation. Dobutamine can provoke arrhytmias even in low
doses.
Case 5
A 66 year-old male patient with a recent (12 days old)
inferior infarction and inferior aneurysm underwent a
high dose dobutamine stress test. A huge aneurysm of the
inferior wall was present on the baseline echocardiogram
(additional file 9). The patient died following an acute
cardiac rupture (additional file 10). Lesson: indications
for testing must always be first class, and in patients with
recent infarction and aneurysm dipyridamole should be
the first choice.
Conclusion
As stated in the American College of Cardiology/American
Heart Association Clinical Competence Statement on
Stress Testing, cognitive skills are required to attain com-
petence in the direct supervision of stress echocardio-
graphic tests, but not only the knowledge of the
complications of different pharmacological agents but
also the knowledge of their complication rate is important
[7]. Therefore, both the patient and the physician, should
be fully aware of the rate of complications during the
application of all forms of stress. It is our stress policy, in
the everyday echo lab activity, to strictly adopt the follow-
ing criteria based on conventional wisdom and evidence-
based medicine: 1) Avoid contraindications; 2) Never
exceed standard dosages; 3) Perform the test after signed
information consent has been obtained; 4) There must
always be an attending physician; 5) Outpatients should
be kept for 60' in the waiting room after testing; 6) Indica-
tions for testing must be class first class.
Additional material
Additional File 1
The baseline echo (apical 4 chamber view) with apical hypokinesis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S1.mpg]
Additional File 2
No change in wall motion, but ventricular tachycardia developed at peak 
stress.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S2.mpg]
Additional File 3
Resting parasternal short axis view and apical 4 chamber view with nor-
mal regional left ventricular wall motion.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
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Additional File 4
Following the dipyridamole administration cardiogenic shock occurred. 
Depressed global left ventricular function can be seen both from paraster-
nal long axis view and apical 4 chamber view.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S4.mpg]
Additional File 5
Apical 4 chamber view during low dose dobutamine.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S5.mpg]
Additional File 6
Parasternal long axis view. The initiation of the torsade de pointe ven-
tricular tachycardia.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S6.mpg]
Additional File 7
Apical 4 chamber view and apical long axis view. Apical and posterior aki-
nesia on the resting images.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S7.mpg]
Additional File 8
Ventricular fibrillation following a low dose dobutamine.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S8.mpg]
Additional File 9
Quad-screen image of a patient with inferior aneurysm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S9.mpg]
Additional File 10
The image of the heart following a cardiac rupture with huge pericardial 
effusion.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-3-25-S10.mpg]